Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

15.98
+0.31001.98%
Post-market: 15.980.0006+0.00%16:49 EDT
Volume:1.99M
Turnover:31.67M
Market Cap:1.51B
PE:-5.06
High:16.33
Open:15.65
Low:15.50
Close:15.67
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:1.00
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:14.25
PE(LYR):-4.72

Loading ...

Unusually active option classes on open July 28th

TIPRANKS
·
Jul 28

US FDA Staff Raise Efficacy Concerns on Replimune's Skin Cancer Drug Ahead of Meeting

Reuters
·
Jul 28

FDA Staff Reviewers Flag Concerns Regarding Replimune's Cancer Drug Trial Ahead of July 30 Advisory Committee Meeting - Briefing Docs

THOMSON REUTERS
·
Jul 28

Replimune Shares Down 25% Premarket After FDA Staff Flags Efficacy Concerns on Co's Skin Cancer Therapy

THOMSON REUTERS
·
Jul 28

Replimune Group put volume heavy and directionally bearish

TIPRANKS
·
Jul 27

Replimune Group put volume heavy and directionally bearish

TIPRANKS
·
Jul 20

Replimune Announces Annual Shareholder Meeting

Reuters
·
Jul 14

Replimune Group put volume heavy and directionally bearish

TIPRANKS
·
Jul 08

Replimune Group is Maintained at Neutral by Wedbush

Dow Jones
·
Jun 30

Replimune price target raised to $9 from $6 at Wedbush

TIPRANKS
·
Jun 30

Replimune Group Inc : Bmo Raises to Outperform from Underperform

THOMSON REUTERS
·
Jun 30

Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating

MT Newswires Live
·
Jun 29

Replimune Group put volume heavy and directionally bearish

TIPRANKS
·
Jun 29

Replimune Group Q4 EPS $(0.76) Misses $(0.71) Estimate

Benzinga Earnings
·
Jun 29

Replimune Group Inc Reports Results for the Quarter Ended March 31 - Earnings Summary

Reuters
·
Jun 29

Replimune's Fiscal Q4 Net Loss Narrows

MT Newswires Live
·
Jun 29

Earnings Flash (REPL) Replimune Posts Fiscal 2026 Net Loss $3.38 a Share, vs. FactSet Est of $3.27 Loss

MT Newswires Live
·
Jun 29

Replimune FY26 Net Loss Widens to $313.94 Million; R&D Expenses Rise to $221.18 Million

Reuters
·
Jun 29

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Jun 29